EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Growth differentiation factor 15 is not modified after weight loss induced by liraglutide in South Asians and Europids with type 2 diabetes mellitus

Carlijn A Hoekx iD, Maaike E Straat, Maurice B Bizino, Huub J van Eyk, Hildebrandus J Lamb, Johannes W A Smit, Ingrid M Jazet, Saskia C A de Jager, Mariëtte R Boon, Borja Martinez-Tellez

Experimental Physiology · 2024

DOI: 10.1113/ep091815 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Experimental Physiology, 2024. Verfasst von Carlijn A Hoekx und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Growth Differentiation Factor 15, Hypoglycemic Agents, Liraglutide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dutch Research Council NWO, Ministerio de Universidades y la Unión Europea-NextGenerationEU.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists induce weight loss in patients with type 2 diabetes mellitus (T2DM), but the underlying mechanism is unclear. Recently, the mechanism by which metformin induces weight loss could be explained by an increase in growth differentiation factor 15 (GDF15), which suppresses appetite. Therefore, we aimed to investigate whether the GLP‐1R agonist liraglutide modifies plasma GDF15 levels in patients with T2DM. GDF15 levels were measured in plasma samples obtained from Dutch Europids and Dutch South Asians with T2DM before and after 26 weeks of treatment with daily liraglutide ( n = 44) or placebo ( n = 50) added to standard care. At baseline, circulating GDF15 levels did not differ between South Asians and Europids with T2DM. Treatment with liraglutide, compared to placebo, decreased body weight, but did not modify plasma GDF15 levels in all patients, or when data were split by ethnicity. Also, the change in plasma GDF15 levels after treatment with liraglutide did not correlate with changes in body weight or HbA 1c levels. In addition, the dose of metformin used did not correlate with baseline plasma GDF15 levels. Compared to placebo, liraglutide treatment for 26 weeks does not modify plasma GDF15 levels in Dutch Europid or South Asian patients with T2DM. Thus, the weight loss induced by liraglutide is likely explained by other mechanisms beyond the GDF15 pathway. Highlights What is the central question of this study? Growth differentiation factor 15 (GDF15) suppresses appetite and is increased by metformin: does the GLP‐1R agonist liraglutide modify plasma GDF15 levels in patients with type 2 diabetes mellitus (T2DM)? What is the main finding and its importance? Plasma GDF15 levels did not differ between South Asians and Europids with T2DM and were not modified by 26 weeks of liraglutide in either ethnicity. Moreover, there was no correlation between the changes in plasma GDF15 levels and dosage of metformin administered, changes in body weight or HbA1c levels. The appetite‐suppressing effect of liraglutide is likely exerted via pathways other than GDF15.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Growth Differentiation Factor 15Hypoglycemic AgentsLiraglutideMetforminWeight LossAgedFemaleHumansMaleMiddle AgedGlucagon-Like Peptide-1 ReceptorSouth Asian PeopleWhite PeopleGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

ethnic differencesmetabolic diseasesobesityweight‐reducing drugs

Substanzen

Glucagon-Like Peptide-1 ReceptorGrowth Differentiation Factor 15Hypoglycemic AgentsLiraglutideMetforminGlucagon-Like Peptide-1 Receptor AgonistsGDF15 protein, human

Autor:innen und Institutionen

  • Division of Endocrinology, Department of Medicine, Leiden University Medical Center, Leiden, The Netherlands.
  • Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Department of Nursing Physiotherapy and Medicine, SPORT Research Group (CTS-1024), CERNEP Research Center, University of Almería, Almería, Spain.

ORCID-Profile: Carlijn A Hoekx

Förderung

  • Dutch Research Council NWO
  • Ministerio de Universidades y la Unión Europea-NextGenerationEU

Zitieren

APA

Hoekx, C. A., Straat, M. E., Bizino, M. B., van Eyk, H. J., Lamb, H. J., Smit, J. W. A., Jazet, I. M., de Jager, S. C. A., Boon, M. R., & Martinez-Tellez, B. (2024). Growth differentiation factor 15 is not modified after weight loss induced by liraglutide in South Asians and Europids with type 2 diabetes mellitus. Experimental Physiology. https://doi.org/10.1113/ep091815

Vancouver

Hoekx CA, Straat ME, Bizino MB, van Eyk HJ, Lamb HJ, Smit JWA, et al. Growth differentiation factor 15 is not modified after weight loss induced by liraglutide in South Asians and Europids with type 2 diabetes mellitus. Experimental Physiology. 2024. doi:10.1113/ep091815

BibTeX
@article{Hoekx2024,
  author = {Hoekx, Carlijn A and Straat, Maaike E and Bizino, Maurice B and van Eyk, Huub J and Lamb, Hildebrandus J and Smit, Johannes W A and Jazet, Ingrid M and de Jager, Saskia C A and Boon, Mariëtte R and Martinez-Tellez, Borja},
  title = {Growth differentiation factor 15 is not modified after weight loss induced by liraglutide in South Asians and Europids with type 2 diabetes mellitus},
  journal = {Experimental Physiology},
  year = {2024},
  doi = {10.1113/ep091815}
}
Kostenlos starten →